• AUM

    ₹ 544.81 Crores

    As on 31-01-2026
  • Benchmark

    Benchmark Riskometer

    Riskometer

    *Investors should consult their financial advisers if in doubt about whether the product is suitable for them

    BSE Healthcare TRI Index

  • Inception Date

    27-06-2025

  • Expense Ratio (Base)

    2.20%
    As on 26-02-2026

Market Capitalization

  • Large Cap
  • Mid Cap
  • Small Cap
  • ETF Cash/Debt

Market Capitalization as per SEBI - Large Cap: 1st - 100th company, Mid Cap: 101st - 250th company and Small Cap: 251st company onwards in terms of full market capitalization

Holdings (Top 5)

Sun Pharmaceutical Industries Limited
8.49%
Mankind Pharma Limited
7.41%
Cipla Limited
6.32%
Max Healthcare Institute Limited
5.8%
Abbott India Limited
4.96%
See All Holdings

Rolling Returns

Historical, annualized average returns, useful for examining the behaviour of returns for a given holding period. For eg: Rolling returns for 5 years are calculated by checking all 5 year time periods across a fund’s history and calculating average/ minimum/ maximum values.

Bars show Return distribution (% of times) in a given range for a selected time period.

6M

1Y

3Y

5Y

10Y

Fund Performance

Last 6 months
1 year
3 years
5 years
Since inception
Regular Plan (% CAGR*) -21.71% N.A. N.A. N.A. -15.80%
Direct Plan (% CAGR*) -20.09% N.A. N.A. N.A. -14.14%
BSE Healthcare TRI (% CAGR*) -19.37% N.A. N.A. N.A. -9.73%
Additional Benchmark Nifty 50 TRI (% CAGR*) 4.52% N.A. N.A. N.A. -1.14%
Value of ₹10,000 Invested In
Last 6 months
1 year
3 years
5 years
Since inception
Regular Plan 8905.45 N.A. N.A. N.A. 9027.83
Direct Plan 8987.39 N.A. N.A. N.A. 9133.66
BSE Healthcare TRI 9023.64 N.A. N.A. N.A. 9409.67
Additional Benchmark Nifty 50 TRI 10227.92 N.A. N.A. N.A. 9932.29
^^ Simple Annualised

Past performance may or may not be sustained in future and is not a guarantee of any future returns. Returns do not take into account the load, if any. Returns are for growth option. Different plans shall have a different expense structure. The performance details provided above are for regular/distributor plan.

Please refer below for fund manager details and performance of other funds managed by the Fund Manager(s)

*Compound annual growth rate

**Benchmark & ***Additional Benchmark

Data As on 31st January 2026 or specified otherwise.

No data available
Note:Performance of the Fund is not provided as the scheme has not completed 6 months.

Loading...

10000

5000000

10000

5000000

Scheme Name

Returns

Investment Value

Total Amount
Withdrawn

Corpus Balance

SWP Period


Disclaimer:

This calculator is provided for informational purposes only.

The results are based on user inputs and should not be considered as investment advice. Users should seek the advice of a qualified financial professional before making any investment decisions.

The creators of the calculator and its affiliates shall not be held responsible for any financial losses resulting from the use of the calculator.

Past performance may or may not be sustained in the future and should not be used as a basis for comparison with other investments. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.

SIP is allowed in select open ended schemes. Refer the Scheme SAI, SID, KIM for detailed information

Loading...

0

100000

Fund BARODA BNP PARIBAS ELSS Tax Saver Fund - Regular - Growth Option

Frequency Monthly

SIP Start Date 05-01-2006

SIP End Date 01-01-2025

Invested Amount ₹22,80,000.00

Current Value ₹1,03,86,141.98

Scheme Returns 14.17%

Benchmark Returns 14.12%

TER (Total Expense Ratio) 2.2%


Disclaimer:

This calculator is provided for informational purposes only.

The results are based on user inputs and should not be considered as investment advice. Users should seek the advice of a qualified financial professional before making any investment decisions.

The creators of the calculator and its affiliates shall not be held responsible for any financial losses resulting from the use of the calculator.

Past performance may or may not be sustained in the future and should not be used as a basis for comparison with other investments. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.

SIP is allowed in select open ended schemes. Refer the Scheme SAI, SID, KIM for detailed information

Fund Details

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be achieved. The Scheme does not guarantee/indicate any returns.

Entry Load : Not applicable
Exit Load: Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment- Exit load -NIL. For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment- 1.00% of applicable NAV. For redemption/switch out of units after 1 year from the date of allotment-Nil. For detailed load structure please refer Scheme Information Document.

(i) Daily, Weekly, Monthly SIP: ₹ 500/- and in multiples of ₹ 1/- thereafter;
(ii) Quarterly SIP: ₹ 1500/- and in multiples of ₹ 1/- thereafter. There is no upper limit for application.

₹ 1,000/- and in multiples of Re. 1/- thereafter per installment, where an investor opts for a Daily/ weekly/ fortnightly/ monthly STP. ₹ 1,500/- and in multiples of Re. 1/- thereafter per installment, where an investor opts for a quarterly STP. STP will be terminated if the amount to be transferred is less than the minimum application amount of the transferee scheme.

₹ 1,000/- and in multiples of Re. 1/- thereafter per installment, where an investor opts for a weekly/ monthly SWP ₹ 1,500/- and in multiples of Re. 1/- thereafter per installment, where an investor opts for a quarterly SWP

Baroda BNP Paribas Health and Wellness Fund

An open ended equity scheme investing in Pharma and Healthcare sector

This product is suitable for investors who are seeking*:
- Long term wealth creation.
- Investment predominantly in equity & equity related instruments of Pharma and Healthcare Companies.

Scheme Riskometer^^

6

Benchmark (Tier 1) Riskometer^

6

^^Riskometer For Scheme: basis it's portfolio, ^Riskometer For Benchmark (e BSE Healthcare TRI Index): basis it's constituents; as on January 31, 2026

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Fund Manager

Sanjay Chawla

Sanjay Chawla

Chief Investment Officer Equity (CIO-Equity)

Managing this fund since July 2025

Performance of Other Funds Managed by Sanjay Chawla